Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
Mo | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
Mo | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
Mo | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights | 45 | GlobeNewswire (Europe) | Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial... ► Artikel lesen | |
28.03. | Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering | 4 | Seeking Alpha | ||
28.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.03. | RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 232 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip... ► Artikel lesen | |
10.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform | 127 | GlobeNewswire (Europe) | SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
28.02. | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 313 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
24.02. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital | 75 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
29.01. | Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 | 2 | GlobeNewswire (USA) | ||
28.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement | 2 | GlobeNewswire (USA) | ||
28.01. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
10.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
10.01. | Why Calidi Biotherapeutics (CLDI) Stock Is Down 30% | 1 | Benzinga.com | ||
10.01. | Calidi Biotherapeutics slumps 29%, prices $4.25M stock offering | 2 | Seeking Alpha | ||
10.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
10.01. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.01. | Calidi Biotherapeutics announces proposed public offering | 3 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 22,905 | -1,78 % | Impfstoff-Aktien Moderna, BioNTech und Co massiv unter Druck - Gegenwind in den USA | Auch zum Start in die neue Handelswoche bahnen sich erneut Kursverluste bei einigen US-gelisteten Aktien aus dem Pharma- und Biotech-Sektor an. Vor allem bei den Impfstoff-Titeln geht es teilweise kräftig... ► Artikel lesen | |
OCUGEN | 0,543 | -6,47 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
VIKING THERAPEUTICS | 21,250 | -3,23 % | Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now? | ||
ALIGOS THERAPEUTICS | 6,200 | +5,08 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen | |
SAGIMET BIOSCIENCES | 2,060 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates | Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational... ► Artikel lesen | |
QIAGEN | 36,135 | -0,18 % | Biotech Report: Qiagen behauptet, Evotec und Biontech rutschen ab | (shareribs.com) Frankfurt / New York 28.03.2025 - Die Biotechnologiewerte entwickeln sich im deutschen Handel uneinheitlich. Für Biontech geht es deutlich abwärts. Auch in den USA zeigt sich der Handel... ► Artikel lesen | |
TEMPUS AI | 46,220 | 0,00 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
BIONTECH | 80,40 | -3,89 % | BioNTech-Aktie: Das tragische Ende! | News von Trading-Treff.de Für die BioNTech sieht es nach einem tragischen Ende des Aufwärtsmarsches aus. Die Mainzer haben auch am Donnerstag einen Abschlag in Höhe von mehr als -1,9 % hinnehmen müssen.... ► Artikel lesen | |
EVOTEC | 5,610 | -4,92 % | Aktie vor 100 %-Rally! Evotec, thyssenkrupp, Vidac Pharma Aktie vor goldenem April? | Können sich Aktionäre bald über 100 % Kursgewinn freuen? Geht es nach Analysten, könnte dies bei Evotec bevorstehen. Allerdings müssen Aktionäre zuvor einen wichtigen Termin im April markieren. Dort... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 43,110 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
AVIDITY BIOSCIENCES | 28,120 | 0,00 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 16,180 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen |